Riley Jeffrey Scott 4

What Happened

• Riley Jeffrey Scott, a director of Gain Therapeutics, was granted a derivative award covering 25,000 shares on July 15, 2026. The filing reports a $0.00 per-share acquisition price (the grant/award is reported as a derivative instrument). No cash sale or open-market purchase occurred.

Key Details

• Transaction date: 2026-07-15; filing date: 2026-07-17 (timely filing).
• Reported price: $0.00 per share (derivative award).
• Shares/units granted: 25,000 (derivative).
• Shares owned after the transaction: Not disclosed in the filing.
• Footnote: The option vests in 12 equal monthly installments commencing July 24, 2026, subject to continuous service through each vesting date (per footnote F1).
• Transaction type code: A = Award/Grant.

Context

• This was an equity award (a derivative option grant), not a market purchase or sale. The award vests monthly over one year and is contingent on continued service, so the shares are not immediately transferable or sold. Such grants are common for compensating directors and do not by themselves indicate a buy/sell decision in the public market.